Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $3.65 million. The enterprise value is -$1.20 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 2.34 million shares outstanding. The number of shares has increased by 1,819.94% in one year.
| Current Share Class | 2.34M |
| Shares Outstanding | 2.34M |
| Shares Change (YoY) | +1,819.94% |
| Shares Change (QoQ) | +147.91% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 1.22% |
| Float | 2.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.42
| Current Ratio | 3.42 |
| Quick Ratio | 3.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -340.81% and return on invested capital (ROIC) is -204.05%.
| Return on Equity (ROE) | -340.81% |
| Return on Assets (ROA) | -57.37% |
| Return on Invested Capital (ROIC) | -204.05% |
| Return on Capital Employed (ROCE) | -211.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.38% in the last 52 weeks. The beta is -0.04, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.04 |
| 52-Week Price Change | -96.38% |
| 50-Day Moving Average | 2.64 |
| 200-Day Moving Average | 9.72 |
| Relative Strength Index (RSI) | 25.66 |
| Average Volume (20 Days) | 865,210 |
Short Selling Information
The latest short interest is 229,818, so 9.82% of the outstanding shares have been sold short.
| Short Interest | 229,818 |
| Short Previous Month | 243,563 |
| Short % of Shares Out | 9.82% |
| Short % of Float | 9.89% |
| Short Ratio (days to cover) | 1.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.11M |
| Pretax Income | -15.90M |
| Net Income | -11.64M |
| EBITDA | -8.08M |
| EBIT | -8.11M |
| Earnings Per Share (EPS) | -$35.80 |
Full Income StatementBalance Sheet
The company has $5.17 million in cash and n/a in debt, giving a net cash position of $5.17 million or $2.21 per share.
| Cash & Cash Equivalents | 5.17M |
| Total Debt | n/a |
| Net Cash | 5.17M |
| Net Cash Per Share | $2.21 |
| Equity (Book Value) | 3.83M |
| Book Value Per Share | 2.49 |
| Working Capital | 3.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.72 million and capital expenditures $1, giving a free cash flow of -$17.72 million.
| Operating Cash Flow | -17.72M |
| Capital Expenditures | 1 |
| Free Cash Flow | -17.72M |
| FCF Per Share | -$7.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
